853687-41-9

Upstream product

• 873073-53-1 C₄₆H₇₅NO₉Si₄ 
• 121056-98-2 3,4,5‐tris(tert‐butyldimethylsilyloxy)benzoic acid 
• 121056-86-8 3,4,5-tris((tert-butyldimethylsilyl)oxy)benzaldehyde 
• 853687-37-3 (-)-ECG-7TBS 
• 853687-44-2 benzyl-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-amine 
• 853687-47-5 2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-ylamine 
• 853687-38-4 5,7,3’,4’-O-tetra-tert-butyldimethylsilylepicatechin 
• 853687-43-1 2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-one 
• 121056-98-2 (3,4,5-tris((tert-butyldimethylsilyl)oxy)phenyl)methanol 
• 853687-49-7 N-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-3,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-benzamide 

Relevant academic research and scientific papers

PYRANS FOR USE IN THE TREATMENT OF INFECTION

There is provided a novel compound of the general formula (I), in which each R is hydrogen, aryl, C1-6 alkyl, trialkylsilyl, or acyl, each R1 is selected from hydroxy, C1-6 alkoxy and acyloxy; each R2 is H, Csu

Synthesis and antibacterial activity of hydrolytically stable (-)-epicatechin gallate analogues for the modulation of β-lactam resistance in Staphylococcus aureus

Hydrolytically more stable analogues of (-)-epicatechin gallate (ECg) have been synthesised from ECg where an amine or amide function has been substituted for the ester linkage that joins the C-ring with the galloyl D-ring. Sub-inhibitory concentrations (